Corium International, Inc. (NASDAQ: CORI)

RM LAW, P.C. is investigating potential claims against the board of directors of Corium International, Inc. (“Corium” or the “Company”) (NASDAQ: CORI) concerning possible breaches of fiduciary duty and other violations of law related to the Company’s efforts to sell the Company to Gurnet Point Capital in a transaction valued at approximately $504 million.

If you own shares of Corium and would like to learn more about this class action or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (844) 291-9299 or to sign up online, click here.  You may also email Mr. Maniskas at rm@maniskas.com.

Under the terms of the agreement, shareholders of Corium will receive $12.50 per share in cash upon the closing. The agreement also provides for a Contingent Value Right of $0.50 per share that is payable based on the U.S. Food and Drug Administration’s approval of Corium’s lead product candidate, Corplex Donepezil, for the treatment of Alzheimer’s disease, prior to March 31, 2020.

Our investigation concerns possible breaches of fiduciary duty and other violations of state law by the board of directors of Corium for not acting in the Company’s shareholders’ best interests in connection with the sale process.